Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma
(FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal
Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy,
vascular occlusion and other retinal disorders.